Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?
Authors
Keywords
-
Journal
Biomed Research International
Volume 2015, Issue -, Pages 1-10
Publisher
Hindawi Limited
Online
2015-06-05
DOI
10.1155/2015/816164
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix
- (2015) Emma Robinson et al. BASIC RESEARCH IN CARDIOLOGY
- Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications
- (2015) Sho-ichi Yamagishi et al. Cardiovascular Diabetology
- Association of low GLP-1 with oxidative stress is related to cardiac disease and outcome in patients with type 2 diabetes mellitus: A pilot study
- (2015) Susana Ravassa et al. FREE RADICAL BIOLOGY AND MEDICINE
- Risk of myocardial infarction in trials with Dipeptidyl Peptidase-4 inhibitors: Is duration of study a real issue?
- (2015) Ilaria Dicembrini et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis
- (2015) Gianluigi Savarese et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients
- (2015) Antoni Sicras-Mainar et al. Diabetes & Metabolism Journal
- Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury
- (2014) Yuichi Terawaki et al. Cardiovascular Diabetology
- Substance P Increases Sympathetic Activity During Combined Angiotensin-Converting Enzyme and Dipeptidyl Peptidase-4 Inhibition
- (2014) Jessica K. Devin et al. HYPERTENSION
- Increased Plasma DPP4 Activity Is Predictive of Prediabetes and Type 2 Diabetes Onset in Chinese Over a Four-Year Period: Result From the China National Diabetes and Metabolic Disorders Study
- (2014) Tianpeng Zheng et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Ectopic Fat in Insulin Resistance, Dyslipidemia, and Cardiometabolic Disease
- (2014) Gerald I. Shulman NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin, Alogliptin, and Cardiovascular Outcomes
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- The role of glucagon on type 2 diabetes at a glance
- (2014) Amélio F Godoy-Matos Diabetology & Metabolic Syndrome
- Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison
- (2014) Paul Craddy et al. Diabetes Therapy
- Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease
- (2013) Jennifer B. Green et al. AMERICAN HEART JOURNAL
- Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner
- (2013) Derek J Hausenloy et al. Cardiovascular Diabetology
- Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor
- (2013) Yuji Ishibashi et al. Cardiovascular Diabetology
- Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial
- (2013) Julio Rosenstock et al. Diabetes & Vascular Disease Research
- Adipose Dipeptidyl Peptidase-4 and Obesity: Correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro
- (2013) H. Sell et al. DIABETES CARE
- Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)
- (2013) D. M. Nathan et al. DIABETES CARE
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
- (2013) E. J. Rhee et al. DIABETES OBESITY & METABOLISM
- CD26/DPP4 Levels in Peripheral Blood and T Cells in Patients With Type 2 Diabetes Mellitus
- (2013) Sang Ah Lee et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Glucose-dependent Insulinotropic Polypeptide: Blood Glucose Stabilizing Effects in Patients With Type 2 Diabetes
- (2013) Mikkel B. Christensen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
- (2013) Samuel S. Engel et al. Diabetes Therapy
- Meta-Analysis of Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Risk in Type 2 Diabetes Mellitus
- (2012) Harshal R. Patil et al. AMERICAN JOURNAL OF CARDIOLOGY
- Glucagon-like peptide-1 preserves coronary microvascular endothelial function after cardiac arrest and resuscitation: potential antioxidant effects
- (2012) Betsy B. Dokken et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
- (2012) Odd Johansen et al. Cardiovascular Diabetology
- A Glucagon-Like Peptide-1 Analog Reverses the Molecular Pathology and Cardiac Dysfunction of a Mouse Model of Obesity
- (2012) Mohammad Hossein Noyan-Ashraf et al. CIRCULATION
- Serum levels of advanced glycation end products (AGEs) are independently correlated with circulating levels of dipeptidyl peptidase-4 (DPP-4) in humans
- (2012) Nobuhiro Tahara et al. CLINICAL BIOCHEMISTRY
- A Potential Role for Dendritic Cell/Macrophage-Expressing DPP4 in Obesity-Induced Visceral Inflammation
- (2012) Jixin Zhong et al. DIABETES
- Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of dipeptidyl peptidase-IV inhibition
- (2012) M. R. Rizzo et al. DIABETES CARE
- Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis
- (2012) C. F. Deacon et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials
- (2012) M. Monami et al. DIABETES OBESITY & METABOLISM
- Endothelial dysfunction in type 2 diabetes
- (2012) A. Natali et al. DIABETOLOGIA
- Cardiovascular Biology of the Incretin System
- (2012) John R. Ussher et al. ENDOCRINE REVIEWS
- GLP-1-dependent and independent effects and molecular mechanisms of a dipeptidyl peptidase 4 inhibitor in vascular endothelial cells
- (2012) Hu Y et al. MOLECULAR BIOLOGY REPORTS
- Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries
- (2011) Veerle Matheeussen et al. BIOLOGICAL CHEMISTRY
- Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome
- (2011) D. Lamers et al. DIABETES
- Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes
- (2011) P. C. M. van Poppel et al. DIABETES CARE
- Therapy in the Early Stage: Incretins
- (2011) S. Cernea et al. DIABETES CARE
- CD26/DPP-4 inhibition recruits regenerative stem cells via stromal cell-derived factor-1 and beneficially influences ischaemia-reperfusion injury in mouse lung transplantation
- (2011) W. Jungraithmayr et al. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
- Glucagon-like Peptide-1 (GLP-1), Immediately Prior to Reperfusion, Decreases Neutrophil Activation and Reduces Myocardial Infarct Size in Rodents
- (2011) B. B. Dokken et al. HORMONE AND METABOLIC RESEARCH
- Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1
- (2011) Gian Paolo Fadini et al. VASCULAR PHARMACOLOGY
- Different modulation of dipeptidyl peptidase-4 activity between microvascular and macrovascular human endothelial cells
- (2010) Laura Pala et al. ACTA DIABETOLOGICA
- Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines
- (2010) Wataru Takasawa et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes: Possible role of stromal-derived factor-1
- (2010) G. P. Fadini et al. DIABETES CARE
- Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population
- (2010) A. Schweizer et al. DIABETES OBESITY & METABOLISM
- A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study
- (2010) C. Filozof et al. DIABETIC MEDICINE
- Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes
- (2010) T. Forst et al. DIABETIC MEDICINE
- Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial
- (2010) B. Göke et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes
- (2010) Robert Frederich et al. POSTGRADUATE MEDICINE
- Endothelial dysfunction in diabetes mellitus: Molecular mechanisms and clinical implications
- (2010) Corey E. Tabit et al. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
- Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside
- (2009) Marc Vanderheyden et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- Pathophysiology of prediabetes
- (2009) Muhammad A. Abdul-Ghani et al. Current Diabetes Reports
- Dipeptidyl Peptidase-4 (CD26): Knowing the Function before Inhibiting the Enzyme
- (2009) E. Matteucci et al. CURRENT MEDICINAL CHEMISTRY
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
- (2009) R. A. DeFronzo DIABETES
- The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
- (2009) R. A. DeFronzo et al. DIABETES CARE
- Adipose tissue as an endocrine organ
- (2009) Sandra Galic et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Inflammation and immunity in diabetic vascular complications
- (2008) Jan Nilsson et al. CURRENT OPINION IN LIPIDOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started